Dr. Reddy's Laboratories Limited (RDY) Stock

Dr. Reddy's Laboratories Limited, along with its subsidiaries, operates as a fully integrated global pharmaceutical company, encompassing diverse segments including Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, and Others. The Global Generics segment focuses on manufacturing and marketing a wide range of prescription and over-the-counter pharmaceutical products, both branded and generic, ensuring therapeutic equivalence to branded formulations. This segment also includes a burgeoning biologics business.

In parallel, the PSAI segment specializes in the production and sale of active pharmaceutical ingredients (APIs) and intermediates, crucial components in the manufacture of finished pharmaceutical products. Additionally, PSAI provides contract research services and customizes manufacturing of APIs and steroids to meet specific customer requirements. Dr. Reddy's Proprietary Products segment is dedicated to pioneering research and development efforts aimed at creating differentiated formulations.

Beyond these core segments, Dr. Reddy's Laboratories Limited is actively engaged in expanding therapeutic options across diverse fields such as oncology and inflammation. Therapeutic categories within its portfolio encompass gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Established in 1984 and headquartered in Hyderabad, India, the company continues to drive innovation through strategic collaborations, exemplified by its partnership with Curis, Inc. to advance small molecule antagonists targeting immuno-oncology and precision oncology targets.